FdaApplication
NDA 050730
Identifiers
- fda_app_no: NDA050730
Properties
| Property | Value |
|---|---|
| applicant_name | PFIZER CENTRAL RESEARCH |
| application_type | NDA |
| approval_date | 1996-06-12 |
Revenue by product
ZITHROMAX
| Period | Revenue |
|---|---|
| Q2 2026 | $42.0M |
| Q1 2026 | $112.0M |
| Q3 2025 | $73.0M |
| Q2 2025 | $56.0M |
| Q1 2025 | $158.0M |
| Q3 2024 | $83.0M |
| Q2 2024 | $74.0M |
| Q1 2024 | $200.0M |
| Q4 2023 | $152.0M |
| Q3 2023 | $60.0M |
| Q2 2023 | $44.0M |
| Q1 2023 | $150.0M |
| Q4 2022 | $81.0M |
| Q3 2022 | $71.0M |
| Q2 2022 | $54.0M |
| Q1 2022 | $125.0M |
| Q4 2021 | $80.0M |
| Q3 2021 | $66.0M |
| Q2 2021 | $43.0M |
| Q1 2021 | $89.0M |
| Q4 2020 | $58.0M |
| Q3 2020 | $25.0M |
| Q2 2020 | $55.0M |
| Q1 2020 | $138.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ZITHROMAX | AZITHROMYCIN | EQ 600MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
1 product